参芪扶正注射液联合CHOP方案治疗恶性淋巴瘤的临床研究  

Clinical Study of Shenqi Fuzheng Injection and Chemotherapy in CHOP Protocol in Treating Malignant Lymphoma

作　　者：王文玲[1] 文小平[1] 韩蕾[1] 马莉[1] 

机构地区：[1]贵阳医学院附属医院肿瘤科,贵阳550004

出　　处：《中国中西医结合杂志》2006年第6期508-510,共3页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：贵州省卫生厅立项课题(2003年4月)

摘　　要：目的比较参芪扶正注射液联合CHOP方案或单纯CHOP方案治疗中度非霍奇金氏恶性淋巴瘤的疗效及不良反应。方法入选的60例中度非霍奇金氏恶性淋巴瘤患者分为两组,观察组32例,采用参芪扶正注射液联合CHOP方案治疗,平均化疗5．7周期。对照组28例,单纯用CHOP方案治疗,平均化疗5．6周期。结果观察组完全缓解(CR)18例,部分缓解(PR)4例,稳定(NC)7例,进展(PD)3例,总有效率为68．8％;对照组CR 13例,PR 4例,NC 7例,PD 4例,总有效率为60．7％。观察组治疗后与对照组比较CD3、CD4、CD4／CD8比值明显升高,CD8明显下降,差异有显著性(P<0．05)。观察组白细胞降低、神经毒性及心脏毒性的发生率明显低于对照组(P<0．01)。观察组生活质量改善较对照组明显(P<0．05)。结论参芪扶正注射液联合CHOP方案治疗中度恶性淋巴瘤可起到减轻化疗的不良反应,使患者化疗依从性更好,增强机体的免疫功能,改善患者生活质量的作用。Objective To compare the efficacy and adverse reaction of chemotherapy in CHOP protocol （CT-CHOP） alone or compared with Shenqi Fuzheng injection （SFI） for treatment of moderate malignant nonHodgkin＇s lymphoma, Methods Sixty patients were divided into 2 groups, the treated group （n = 32） treated with CT-CHOP plus SFI for 5.7 cycles on average and the control group （ n = 28） treated with CT-CHOP alone for 5.6 cycles on average. Results In the treated group, 18 patients were completely remitted （CR）, 4 were partially remitted （PR）, 7 were unchanged （NC）, 3 were progressively deteriorated （PD）, with the total remission rate of 68.8%, while in the control group, 13 were CR, 4 PR, 7 NC and 4 PD, the total remission rate being 60.7 %. After treatment, the levels of CD3, CD4 and CD4/CD8 increased and CD8 decreased significantly in the treated group （P 〈0.05）. Patients＇ quality of life （QOL） in the treated group was improved more obviously than that in the control group （P 〈 0.01）, and the incidence rate of adverse reaction as leucopenia, neurotoxicity, and cardiac toxicity were lower in the treated group than those in the control group （P〈0.01）. Conclusion Shenqi Fuzheng injection combined with CT-CHOP on malignant non-Hodgkin＇s lymphoma can reduce the adverse reaction of chemotherapy, ameliorate the compliance of patients to chemotherapy, and improve the immune function and QOL of patients.

关 键 词：参芪扶正注射液 恶性淋巴瘤 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]